A cocktail of AstraZeneca antibodies has given results deemed positive by the pharmaceutical company in phase 3 clinical trials against Covid-19, according to a statement on Monday.
The trial of the drug AZD7442, a combination of antibodies, "produced a statistically satisfactory reduction" in "severe Covid-19 cases or deaths from disease compared to placebo in outpatients with symptoms mild to moderate ”Covid-19, details the AstraZeneca press release.
A total of 90% of the participants were in categories of patients deemed to be at high risk of developing severe forms of Covid-19, including those with co-morbidities. Participants received treatment within five days of onset of symptoms, and preliminary analysis of results shows that “AZD7442 reduced the risk of developing serious or fatal Covid-19 in 67% of cases compared to a placebo, ”the statement said.
AstraZeneca will present the data to health authorities and has already submitted an application for authorization for the use of the drug in the treatment of Covid-19 with the United States Medicines Authority (FDA).
The Swedish-British group announced in March an agreement with the United States to provide the country this year with up to 700,000 doses of this antibody treatment for a total amount of agreements signed with the United States covering 726 million dollars.
Health
Covid-19: A large French study confirms the effectiveness of vaccines, which reduce the risk of hospitalization by 90%
World
Coronavirus: Sydney residents finally come out of almost four months of confinement
Medication
Covid 19
Vaccine
Health
Coronavirus
United States
AstraZeneca